Trinity Biotech【TRIB】銘柄情報

Trinity Biotech PLC (TRIB) 銘柄情報

ポートフォリオを強化: リアルタイムのディスカッションと実用的な取引アイデア。

プレミアム

通貨

0.6616

( -3.77% )

買値

0.6503

売値

0.70

出来高

174,903

0.6561 日の範囲 0.71899

0.5012 52 週間の範囲 3.44

時価総額

13.398M

前日終値

0.6875

始値

0.673

時刻

0.6748

最終取引時間

財務取引量

US$ 118,132

VWAP

0.675412

平均取引量 (3 か月)

US$ 160,051

発行済株式数

20,250,869

配当利回り

PER

-0.34

1 株当たり利益 (EPS)

-2

歳入

43.79M

純利益

-37.38M

Trinity Biotech plc acquires, together with its subsidiaries, develops, acquires, manufactures, and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market in the Americas, Asia, Africa, and Europe. The company offers clinical laborat... Trinity Biotech plc acquires, together with its subsidiaries, develops, acquires, manufactures, and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market in the Americas, Asia, Africa, and Europe. The company offers clinical laboratory products, including diagnostic tests and instrumentation, which detects infectious diseases; sexually transmitted diseases, such as syphilis and herpes; SARS-CoV-2; and epstein barr, measles, mumps, toxoplasmosis, cytomegalovirus, rubella, varicella and other viral pathogens, as well as products for the in-vitro diagnostic measurement of haemoglobin A1c used in the monitoring and diagnosis of diabetes, and identifying those who are at a risk of developing diabetes. It also provides laboratory-testing services for Sjogren’s syndrome, hearing loss, celiac disease, lupus, rheumatoid arthritis, systemic sclerosis, and other laboratory-testing services for autoimmune disorders. In addition, the company develops, manufactures, and sells products in the immunofluorescence assay, enzyme-linked immunosorbent, western blot, and line immunoassay formats; and provides reagent products, such as ACE, bile acids, oxalate, and glucose-6-phosphate dehydrogenase for diagnosis of liver and kidney diseases, as well as haemolytic anaemia. It serves public health authorities, and clinical and reference laboratories through its direct sales force, as well as through a network of independent distributors and strategic partners. It has a collaboration agreement with a bioinformatics company to conduct analysis on clinical trial data for EpiCapture, a molecular diagnostics company for developing a non invasive urine based prognostic test for progression to aggressive prostate cancer. Trinity Biotech plc was incorporated in 1992 and is headquartered in Bray, Ireland. 詳細を表示

セクター

Healthcare

業界

Medical Diagnostics & Screening

ウェブサイト

www.trinitybiotech.com

本社

Bray, Ireland

設立

1992

Trinity Biotech PLC is listed in the Healthcare sector of the ナスダック市場 with ticker TRIB. The last closing price for Trinity Biotech was US$0.69. Over the last year, Trinity Biotech shares have traded in a share price range of US$ 0.5012 to US$ 3.44.

Trinity Biotech currently has 20,250,869 shares in issue. The market capitalisation of Trinity Biotech is US$13.40 million. Trinity Biotech has a price to earnings ratio (PE ratio) of -0.34.

期間 †	前日比	前日比 %	始値	高値	安値	平均出来高	VWAP
1	-0.0734	-9.98639455782	0.735	0.75	0.65	143635	0.67598577	DR
4	0.0816	14.0689655172	0.58	0.75	0.5596	148237	0.65139767	DR
12	-0.0284	-4.11594202899	0.69	0.75	0.5012	129881	0.63868597	DR
26	-0.4584	-40.9285714286	1.12	1.68	0.5012	1624120	1.2041533	DR
52	0.0016	0.242424242424	0.66	3.44	0.5012	2103865	1.47413983	DR
156	-0.3784	-36.3846153846	1.04	3.55	0.37	1053250	1.50757448	DR
260	-2.6184	-79.8292682927	3.28	3.55	0.37	693677	1.50034489	DR